News
Another COVID-19 vaccine, Moderna, records 94.5% success
The quest for effective vaccines to combat the ravaging coronavirus has recorded another breakthrough with a United States-based biotech firm, Moderna Inc, saying on Monday that its experimental vaccine was 94.5 per cent effective in preventing the disease, according to an analysis of its clinical trial.
The report from multiple sources including BBC, Reuters and The Guardian comes a week after Pfizer and BioNTech said their vaccine was more than 90 per cent effective.
The results for both vaccines were from interim analyses of large clinical studies.
An interim analysis of the Moderna released on Monday, and based on 95 patients with confirmed COVID-19 infections found the candidate vaccine has an efficacy of 94.5 per cent.
In the result from the Moderna study, there were 30,000 volunteers; half got two doses of the vaccine 28 days apart; half got two shots of a placebo on the same schedule.
There were 95 instances of COVID-19 illness among the study participants — only five of those cases were in the vaccinated group. Ninety were in the group receiving the placebo.
Of these, there were said to be 11 cases of severe disease. The results indicate the vaccine was inducing the kind of immune response that protects people if they were exposed to the coronavirus.
Chief Executive Officer of Moderna, Stéphane Bancel, was quoted as saying in a statement, “This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease.”
Moderna said it had improved the shelf life and stability of its own vaccine, meaning that it can be stored at standard refrigeration temperatures of 2C to 8C for 30 days.
The company said it planned to apply to the US regulator, the Food and Drug Administration, for emergency-use authorisation in the coming weeks.
The results are the latest encouraging news to emerge from the breakneck effort to develop a vaccine against coronavirus and follow a similar interim analysis earlier this month from a collaboration between Pfizer and the German firm BioNTech, which suggest its vaccine is 90 per cent effective at preventing illness.
The Moderna vaccine is however not expected to be available outside the US until next year.
The biotech company said it would have 20m doses ready to ship in the US before the end of 2020 and hoped to manufacture 500 million to one billion doses globally next year.
So far, the UK does not stand to benefit from the vaccine. Moderna has agreed to provide the US with 100 million doses, with an option to buy 400m more. Japan, Canada, Switzerland, Qatar and Israel have also signed agreements, and the European commission has a “potential purchase agreement” for 80m-160m doses. The UK chose not to participate in the EU vaccine purchase scheme, with the health secretary, Matt Hancock, arguing in July that the government could source vaccine faster on its own. However, a Whitehall source said the UK government was in “advanced discussions” to procure doses of the Moderna vaccine.
The Moderna vaccine, which is based on similar mRNA technology as BioNTech’s, is expected to be assessed by the FDA on a final analysis of 151 COVID cases among trial participants who will be followed on average for more than two months.
If the results remain as impressive as the trial goes on, the Moderna vaccine could potentially provide a major advantage over the Pfizer vaccine.
While Pfizer’s vaccine requires ultracold freezing between -70C and -80C from production facility to patient, Moderna said it had improved the shelf life and stability of its own vaccine, meaning that it can be stored at standard refrigeration temperatures of 2C to 8C for 30 days.
It could be stored for six months at -20C for shipping and long-term storage, the company said.
Cost and side effects
At £38 to £45 for a course of two shots, Moderna’s vaccine is more expensive than the other frontrunners. AstraZeneca and Oxford University are aiming to sell their vaccine at about £3 a dose, while vaccines in trial with Johnson and Johnson and collaboration between Sanofi and GSK are both expected to cost about £8 a dose.
Pfizer is charging the US about £30 for a two-shot course. The UK has ordered 40 million Pfizer shots but none of the Moderna vaccine.
Moderna’s two-shot vaccine injects genetic material called mRNA into the body, which cells then use to churn out the spike protein the virus uses to invade cells.
The spike protein covers the surface of the virus and is one of the main targets of the body’s immune response to wipe out the infection.
A question mark that remains over the Pfizer vaccine is whether it prevents serious illness.
The Moderna results, released by an independent data safety monitoring board, are encouraging on this point. Of 11 participants who developed severe COVID while on the trial, all were in the placebo group. The results also suggest the vaccine is effective in older people and those from diverse ethnic backgrounds.
Moderna’s interim analysis includes a safety review of data available so far.
The company said it had found no significant safety concerns, with most reactions being mild to moderate and short-lived.
Among the side effects reported is the injection site pain in 2.7 per cent of trial volunteers after the first jab.
After the second, the most significant side effects include fatigue in 9.7 per cent, muscle pain in nine per cent and joint pain in five per cent. Others had headaches; others pains, or redness at the injection site.
Peter Openshaw, professor of experimental medicine at Imperial College, London, said the Moderna results were “tremendously exciting” and boosted optimism that a choice of good COVID vaccines would be available in the next few months.
![]()
News
Tinubu Vows to Secure Nigeria, Declares Unity Non-Negotiable Amid Worsening Insecurity
News
Ronaldo Marries Georgina Rodriguez in Intimate Portugal Wedding Ceremony
Ronaldo Marries Georgina Rodriguez in Intimate Portugal Wedding Ceremony
![]()
Education
Nigerian Young Academy, LASU to Host 16th International Conference on Convergent Research
Nigerian Young Academy, LASU to Host 16th International Conference on Convergent Research
Five-day event to bring together academics, policymakers, industry leaders to explore interdisciplinary solutions to global challenges
LAGOS — The Nigerian Young Academy (NYA), in collaboration with Lagos State University (LASU), will host its 16th International Conference and General Assembly from 16 to 20 August 2026 at the LASU Ojo Campus, Lagos, the organisers have announced.
The conference, themed “Convergent Research for Global Impact: Integrating Knowledge, Innovation and Policy,” will convene academics, researchers, policymakers, industry leaders, development partners, and civil society organisations from Nigeria and around the world to examine how interdisciplinary research can address complex societal and global challenges.
According to a press release issued by the Academy, the conference aims to showcase cutting-edge research, strengthen collaboration among emerging and established scholars, and promote evidence-based policies that support sustainable development. It underscores the Nigerian Young Academy’s commitment to advancing research excellence, innovation, and leadership.
The five-day programme will feature keynote and plenary sessions, lead paper presentations, oral and poster presentations, scientific awards, networking opportunities, and a pre-conference workshop on “Building Research Capacity in the AI Era: Grant Writing and Practical Data Analysis Using R.”
READ ALSO:
- 2027 Elections: Atiku Raises Alarm Over Outdated BVAS Software, Warns of Manipulation Risks
- Nigerian Army Opens 2026/2027 Short Service Combatant Commission Recruitment – Apply Now
- US, Iran Nearing Peace Agreement, Pakistan Defence Minister
Discussions will span a broad range of themes, including sustainable development, public health systems, disease prevention, urban resilience, smart cities, energy systems, environmental policy, human-centred technology, rural development, food security, agribusiness, ethics in convergence science, and the application of artificial intelligence and machine learning in governance, planning, and risk assessment.
Keynote and Hosts
The conference keynote address will be delivered by Professor Akin Abayomi, Lagos State Commissioner for Health. Professor Temitope Onuminya, President of the Nigerian Young Academy, will host the event, while Professor Ibiyemi I. Olatunji-Bello, Vice-Chancellor of Lagos State University, will serve as Chief Host.
Call for Abstracts and Registration
Researchers are invited to submit abstracts of no more than 250 words between 1 March and 14 June 2026, while submissions for poster presentations will remain open until 24 July 2026. The conference is open to participants from Nigeria and abroad.
According to the Chairman of the Local Organising Committee, Associate Professor Abdul-Azeez Adeyemi Anjorin of Lagos State University, the conference provides an important platform for researchers, professionals, and policymakers to exchange ideas, foster partnerships, and develop innovative solutions that can shape the future of research, innovation, and public policy.
Scholars, students, professionals, and stakeholders across academia, government, industry, and civil society are encouraged to participate. Registration details and additional information are available through the Nigerian Young Academy website.
About the Nigerian Young Academy
The Nigerian Young Academy (NYA) is Nigeria’s foremost interdisciplinary academy for outstanding early-career researchers and professionals. Established in 2010 by the Nigeria Academy of Science, with the support of the Nigeria Academy of Education and the Nigeria Academy of Engineering, the Academy promotes research excellence, leadership, interdisciplinary collaboration, and public engagement.
The NYA is affiliated with the International Science Council, the Global Young Academy, and the Network of African Science Academies (NASAC). Through its conferences, awards, publications, and capacity-building initiatives, the Academy supports the development of young researchers and contributes to national and global development through science, scholarship, and innovation.
For further information, contact:
Dr. Abdulmalik Salman
Conference Organising Committee, Nigerian Young Academy (NYA)
Email: amas2k7@gmail.com
Telephone: +2347039632128
Website: https://nigerianyoungacademy.org
Nigerian Young Academy, LASU to Host 16th International Conference on Convergent Research
![]()
-
Sports2 days agoAfter Cameroon Heartbreak, Falcons Battle Banyana Thursday for World Cup Lifeline
-
Business2 days agoXenophobia: MTN, Stanbic IBTC, other South African firms face pressure in Nigeria
-
Politics2 days agoAregbesola: I’ve never slept with another woman since marriage
-
metro2 days ago“I Begged for Years” – Nigerian Man Says Wife Never Forgave Him Over Social Media Incident
-
metro2 days agoISWAP Executes Four Shura Council Members Amid Deepening Leadership Crisis
-
News3 days agoItaly-Based Businessman Excretes 98 Wraps of Cocaine at Enugu Airport
-
News2 days agoNigeria Immigration Deploys Passport Intervention Team to UK to Clear Application Backlog
-
Education2 days agoNigerian Mother Gifts Son a Live Goat After Polytechnic Graduation

You must be logged in to post a comment Login